Artiva Biotherapeutics Announces Upsized $167M IPO
July 24, 2024
July 24, 2024
PALO ALTO, California, July 24 -- Cooley, a law firm, issued the following news release:
San Diego - July 22, 2024 - Cooley advised Artiva Biotherapeutics, a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, on its upsized $167 million initial public offering (IPO).
The IPO was for 13,920,000 shares of common stock at a price to the public of $12 p . . .
San Diego - July 22, 2024 - Cooley advised Artiva Biotherapeutics, a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, on its upsized $167 million initial public offering (IPO).
The IPO was for 13,920,000 shares of common stock at a price to the public of $12 p . . .